-
170,000 people in England to have further treatment choice for preventing migraine attacks.
In final draft guidance published today NICE has recommended atogepant, the first of a new type of oral treatment option for preventing both chronic and episodic migraines, opening the way for up to 170,000 people to choose it on the NHS in England.
-
Children and young adults to benefit after NICE recommends personalised immunotherapy to treat blood cancer be made routinely available on the NHS
Innovative CAR-T therapy recommended to treat an aggressive form of leukaemia
-
NICE launches second consultation on genetic testing to guide treatment after a stroke
People could be offered a genetic test in the immediate period after having a stroke to help identify the most suitable treatment to reduce their risk of further strokes.
-
25,000 people to benefit after NICE recommends new ulcerative colitis treatment
New one-a-day pill recommended on the same day the treatment was granted a licence by the MHRA
-
NICE publishes final draft guidance on Enhertu after commercial discussions conclude without a price to make it a cost-effective use of NHS resources.
NICE has published final draft guidance that does not recommend Enhertu (also called trastuzumab deruxtecan and made by Daiichi Sankyo) for treating advanced HER2-low breast cancer in adults.
-
New treatment option available today for womb cancer
A new treatment option given with chemotherapy is recommended for some types of advanced or recurrent womb cancer in final draft NICE guidance published today.
-
A public consultation on our new approach to prioritising guidance is now open
Running for 4 weeks, the consultation seeks your views about our plans to make topic selection and prioritisation more integrated, effective and timely.
-
Up to 14,000 people could benefit from the first treatment for severe alopecia recommended by NICE
New one-a-day tablet for people with severe hair loss due to alopecia areata recommended by NICE
-
Updated NICE guidance recommends more targeting of antibiotics to those at the highest risk of suspected sepsis 
NICE recommends better targeting of antibiotics for suspected sepsis to ensure the right people receive treatment